Publications by authors named "S M Bain"
Background: People with diabetes are at increased risk of hospitalisation, morbidity, and mortality following SARS-CoV-2 infection. Long-term outcomes for people with diabetes previously hospitalised with COVID-19 are, however, unknown. This study aimed to determine the longer-term physical and mental health effects of COVID-19 in people with and without diabetes.
View Article and Find Full Text PDFIntroduction: Heterotopic ossification (HO) occurs following orthopedic trauma, spinal cord injuries, brain trauma and limb amputations. Once symptomatic, HO causes pain, limited mobility and decreased quality of life. Current treatments are limited and have significant complications with high recurrence rates, underscoring the need for improved therapeutic interventions.
View Article and Find Full Text PDFIntroduction: The high risk of cardiovascular events in people with type 2 diabetes increases with age. The cardiovascular effects of once-weekly subcutaneous and once-daily oral semaglutide versus placebo in people with type 2 diabetes at high cardiovascular risk were investigated in the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials, respectively. It is unknown whether the effects of semaglutide are age dependent.
View Article and Find Full Text PDFCurrent management of chronic kidney disease in type-2 diabetes-A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) guidelines.
Diabet Med
February 2025
Article Synopsis
- A significant number of people with diabetes develop chronic kidney disease (CKD), which often leads to end-stage kidney disease (ESKD) and is highly associated with cardiovascular disease (CVD) mortality.
- Managing modifiable risk factors, such as hyperglycemia and hypertension, along with treating dyslipidemia is vital for patients with type 2 diabetes and CKD to reduce the risk of CVD.
- Recent clinical trials demonstrate that medications like SGLT-2 inhibitors and GLP-1 receptor agonists can help protect kidney function in these patients, informing updated clinical practice guidelines for healthcare professionals.
Article Synopsis
- Researchers monitored nine cyclists using glucose sensors during a training camp to analyze their interstitial glucose (iG) levels across different times of the day.
- The study found that on average, cyclists spent 93% of the time in the normal glucose range, 8% below, and 3% above that range, with daytime glucose levels being significantly higher than nighttime levels.
- The findings suggest that lower glucose levels during the night could have implications for non-diabetics and highlight the need for further research on glucose management in athletes.